A ICOPE Intense Program Combined With Ketone Ester Pilot Study

Status: Recruiting
Location: See location...
Intervention Type: Dietary supplement, Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

ICOPE could constitute the reference model of care for healthy aging. More specifically, our hypothesis is that the intervention implemented in ICOPE may directly or indirectly prevent immuno-senescence, the loss of mobility and the cognitive decline. In future Geroscience clinical trials, ICOPE-Intense could become a benchmark to reduce the rate of aging with a strong non-pharmacological intervention and state a reference intervention to compare with new gerotherapeutic drugs.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 65
Maximum Age: 85
Healthy Volunteers: t
View:

• Independent-living (ADL ≥5/6)

• Men and women

• Mobility impairment (5 Chair-rise test \>12 seconds)

• Sedentarism (spend six or more hours per day sitting or lying down)

• Positive screening for cognitive impairment according to the ICOPE screening tool with MMSE \[25-28\]

• BMI ≥25 kg/m2

Locations
Other Locations
France
Cité de la santé - Hopital La Grave
RECRUITING
Toulouse
Contact Information
Primary
Yves ROLLAND
rolland.y@chu-toulouse.fr
0534557607
Time Frame
Start Date: 2025-07-09
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 40
Treatments
Experimental: ICOPE-intense group
ICOPE intense intervention + placebo
Experimental: The ICOPE-intense + Ketone Ester (KE) group
ICOPE intense intervention + nutritional ketone esther suplementation
Experimental: The Ketone group
Usual ICOPE step 1 + ketone esther supplementation
Placebo_comparator: Control group
Usual ICOPE step 1 + placebo
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Toulouse

This content was sourced from clinicaltrials.gov